1
|
Sharma V, Sharma A, Wadje BN, Bharate SB. Benzopyrone, a privileged scaffold in drug discovery: An overview of FDA-approved drugs and clinical candidates. Med Res Rev 2024; 44:2035-2077. [PMID: 38532246 DOI: 10.1002/med.22032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Revised: 02/02/2024] [Accepted: 03/04/2024] [Indexed: 03/28/2024]
Abstract
Natural products have always served as an important source of drugs for treating various diseases. Among various privileged natural product scaffolds, the benzopyrone class of compounds has a substantial presence among biologically active compounds. One of the pioneering anticoagulant drugs, warfarin approved in 1954 bears a benzo-α-pyrone (coumarin) nucleus. The widely investigated psoriasis drugs, methoxsalen, and trioxsalen, also contain a benzo-α-pyrone nucleus. Benzo-γ-pyrone (chromone) containing drugs, cromoglic acid, and pranlukast were approved as treatments for asthma in 1982 and 2007, respectively. Numerous other small molecules with a benzopyrone core are under clinical investigation. The present review discusses the discovery, absorption, distribution, metabolism, excretion properties, and synthetic approaches for the Food and Drug Administration-approved and clinical-stage benzopyrone class of compounds. The role of the pyrone core in biological activity has also been discussed. The present review unravels the potential of benzopyrone core in medicinal chemistry and drug development.
Collapse
Affiliation(s)
- Venu Sharma
- Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, Jammu and Kashmir, India
| | - Ankita Sharma
- Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, Jammu and Kashmir, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India
| | - Bhagyashri N Wadje
- Department of Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana, India
| | - Sandip B Bharate
- Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, Jammu and Kashmir, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India
- Department of Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana, India
| |
Collapse
|
2
|
de Oliveira SV, Neves FDD, dos Santos DC, Monteiro MBB, Schaufelberger MS, Motta BN, de Oliveira IP, Setúbal Destro Rodrigues MF, Franco ALDS, Cecatto RB. The effectiveness of phototherapy for surface decontamination against SARS-Cov-2. A systematic review. JOURNAL OF BIOPHOTONICS 2023; 16:e202200306. [PMID: 36560919 PMCID: PMC9880673 DOI: 10.1002/jbio.202200306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Revised: 12/19/2022] [Accepted: 12/20/2022] [Indexed: 06/17/2023]
Abstract
COVID-19 appeared in December 2019, needing efforts of science. Besides, a range of light therapies (photodynamic therapy, ultraviolet [UV], laser) has shown scientific alternatives to conventional decontamination therapies. Investigating the efficacy of light-based therapies for environment decontamination against SARS-CoV2, a PRISMA systematic review of Phototherapies against SARS-CoV or MERS-CoV species discussing changes in viral RT-PCR was done. After searching MEDLINE/PubMed, EMBASE, and Literatura Latino-Americana e do Caribe em Ciências da Saúde we have found studies about cell cultures irradiation (18), blood components irradiation (10), N95 masks decontamination (03), inanimate surface decontamination (03), aerosols decontamination (03), hospital rooms irradiation (01) with PDT, LED, and UV therapy. The best quality results showed an effective low time and dose UV irradiation for environments and inanimate surfaces without human persons as long as the devices have safety elements dependent on the surfaces, viral charge, humidity, radiant exposure. To interpersonal contamination in humans, PDT or LED therapy seems very promising and are encouraged.
Collapse
Affiliation(s)
- Susyane Vieira de Oliveira
- Post Graduate Program Biophotonics Applied to Health Sciences, Universidade Nove de Julho/UNINOVESao PauloBrazil
| | | | | | | | | | | | | | | | | | - Rebeca Boltes Cecatto
- Post Graduate Program Biophotonics Applied to Health Sciences, Universidade Nove de Julho/UNINOVESao PauloBrazil
- Instituto do Cancer do Estado de Sao Paulo, School of Medicine of the University of Sao PauloSao PauloBrazil
| |
Collapse
|
3
|
Kumar A, Raj A, Gupta A, Gautam S, Kumar M, Bherwani H, Anshul A. Pollution free UV-C radiation to mitigate COVID-19 transmission. GONDWANA RESEARCH : INTERNATIONAL GEOSCIENCE JOURNAL 2023; 114:78-86. [PMID: 35936028 PMCID: PMC9345658 DOI: 10.1016/j.gr.2022.07.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 06/23/2022] [Accepted: 07/03/2022] [Indexed: 06/02/2023]
Abstract
The high rate of transmission of the COVID-19 virus has brought various types of disinfection techniques, for instance, hydrogen peroxide vaporization, microwave generating steam, UV radiation, and dry heating, etc. to prevent the further transmission of the virus. The chemical-based techniques are predominantly used for sanitization of hands, buildings, hospitals, etc. However, these chemicals may affect the health of humans and the environment in unexplored aspects. Furthermore, the UV lamp-based radiation sanitization technique had been applied but has not gained larger acceptability owing to its limitation to penetrate different materials. Therefore, the optical properties of materials are especially important for the utilization of UV light on such disinfection applications. The germicidal or microorganism inactivation application of UV-C has only been in-use in a closed chamber, due to its harmful effect on human skin and the eye. However, it is essential to optimize UV for its use in an open environment for a larger benefit to mitigate the virus spread. In view of this, far UV-C (222 nm) based technology has emerged as a potential option for the sanitization in open areas and degradation of microorganisms present in aerosol during the working conditions. Hence, in the present review article, efforts have been made to evaluate the technical aspects of UV (under the different spectrum and wavelength ranges) and the control of COVID 19 virus spread in the atmosphere including the possibilities of the human body sanitization in working condition.
Collapse
Affiliation(s)
- Ashutosh Kumar
- CSIR-National Environmental Engineering Research Institute (CSIR-NEERI), Nagpur 440020, India
| | - Abhishek Raj
- CSIR-National Environmental Engineering Research Institute (CSIR-NEERI), Nagpur 440020, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
| | - Ankit Gupta
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
- CSIR-NEERI, Delhi Zonal Centre, Naraina Industrial Area, New Delhi 110028, India
| | - Sneha Gautam
- Karunya Institute of Technology and Sciences, Karunya Nagar, Coimbatore 641114, India
| | - Manish Kumar
- Experimental Research Laboratory, Department of Physics, ARSD College, University of Delhi, New Delhi 110021, India
| | - Hemant Bherwani
- CSIR-National Environmental Engineering Research Institute (CSIR-NEERI), Nagpur 440020, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
| | - Avneesh Anshul
- CSIR-National Environmental Engineering Research Institute (CSIR-NEERI), Nagpur 440020, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
| |
Collapse
|
4
|
Abolmaaty A, Amin DH, Abd El-Kader RMM, ELsayed AF, Soliman BSM, Elbahnasawy AS, Sitohy M. Consolidating food safety measures against COVID-19. J Egypt Public Health Assoc 2022; 97:21. [PMID: 36319882 PMCID: PMC9626693 DOI: 10.1186/s42506-022-00112-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 08/08/2022] [Indexed: 11/05/2022]
Abstract
Background The world is facing an extraordinarily unprecedented threat from the COVID-19 pandemic triggered by the SARS-CoV-2 virus. Global life has turned upside down, and that several countries closed their borders, simultaneously with the blockage of life cycle as a result of the shutdown of the majority of workplaces except the food stores and some few industries. Main body In this review, we are casting light on the nature of COVID-19 infection and spread, the persistence of SARS-CoV-2 virus in food products, and revealing the threats arising from the transmission of COVID-19 in food environment between stakeholders and even customers. Furthermore, we are exploring and identifying some practical aspects that must be followed to minimize infection and maintain a safe food environment. We also present and discuss some World Health Organization (WHO) guidelines-based regulations in food safety codes, destined to sustain the health safety of all professionals working in the food industry under this current pandemic. Conclusion The information compiled in this manuscript is supporting and consolidating the safety attributes in food environment, for a prospective positive impact on consumer confidence in food safety and the citizens’ public health in society. Some research is suggested on evaluating the use and potentiality of native and chemical modified basic proteins as possible practices aiming at protecting food from bacterial and viral contamination including COVID-19.
Collapse
Affiliation(s)
- Assem Abolmaaty
- Department of Food Science, Faculty of Agriculture, Ain Shams University, Cairo, Egypt
| | - Dina H Amin
- Department of Microbiology, Faculty of Science, Ain Shams University, Cairo, 1566, Egypt.
| | - Reham M M Abd El-Kader
- Radiation Microbiology Department, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.
| | - Alaa F ELsayed
- Department of Microbiology, Faculty of Science, Ain Shams University, Cairo, 1566, Egypt
| | - Basma S M Soliman
- Department of Biochemistry and Nutrition, National Food Safety Authority, Cairo, Egypt
| | - Amr S Elbahnasawy
- Department of Bioecology, Hygiene and Public Health, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.,Department of Nutrition and Food Sciences, National Research Centre, Giza, Egypt
| | - Mahmoud Sitohy
- Department of Biochemistry, Faculty of Agriculture, Zagazig University, Zagazig, 44511, Egypt
| |
Collapse
|
5
|
Snyder EL, Wheeler AP, Refaai M, Cohn CS, Poisson J, Fontaine M, Sehl M, Nooka AK, Uhl L, Spinella P, Fenelus M, Liles D, Coyle T, Becker J, Jeng M, Gehrie EA, Spencer BR, Young P, Johnson A, O'Brien JJ, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla ST, Lin J, Liu K, Bentow S, Peng H, Varrone J, Benjamin RJ, Corash LM. Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. Transfusion 2022; 62:1365-1376. [PMID: 35748490 PMCID: PMC9544211 DOI: 10.1111/trf.16987] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 05/03/2022] [Accepted: 05/10/2022] [Indexed: 12/15/2022]
Abstract
BACKGROUND Platelet transfusion carries risk of transfusion-transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion-related acute lung injury and acute respiratory distress syndrome (ARDS) occur with platelet transfusion. STUDY DESIGN An open label, sequential cohort study of transfusion-dependent hematology-oncology patients was conducted to compare pulmonary safety of PRPC with conventional PC (CPC). The primary outcome was the incidence of treatment-emergent assisted mechanical ventilation (TEAMV) by non-inferiority. Secondary outcomes included: time to TEAMV, ARDS, pulmonary AEs, peri-transfusion AE, hemorrhagic AE, transfusion reactions (TRs), PC and red blood cell (RBC) use, and mortality. RESULTS By modified intent-to-treat (mITT), 1068 patients received 5277 PRPC and 1223 patients received 5487 CPC. The cohorts had similar demographics, primary disease, and primary therapy. PRPC were non-inferior to CPC for TEAMV (treatment difference -1.7%, 95% CI: (-3.3% to -0.1%); odds ratio = 0.53, 95% CI: (0.30, 0.94). The cumulative incidence of TEAMV for PRPC (2.9%) was significantly less than CPC (4.6%, p = .039). The incidence of ARDS was less, but not significantly different, for PRPC (1.0% vs. 1.8%, p = .151; odds ratio = 0.57, 95% CI: (0.27, 1.18). AE, pulmonary AE, and mortality were not different between cohorts. TRs were similar for PRPC and CPC (8.3% vs. 9.7%, p = .256); and allergic TR were significantly less with PRPC (p = .006). PC and RBC use were not increased with PRPC. DISCUSSION PRPC demonstrated reduced TEAMV with no excess treatment-related pulmonary morbidity.
Collapse
Affiliation(s)
| | | | - Majed Refaai
- University of Rochester Medical CenterRochesterNew YorkUSA
| | - Claudia S. Cohn
- University of Minnesota Medical CenterMinneapolisMinnesotaUSA
| | | | | | - Mary Sehl
- UCLA Medical CenterLos AngelesCaliforniaUSA
| | | | - Lynne Uhl
- Harvard University – Beth Israel Deaconess HospitalBostonMassachusettsUSA
| | - Philip Spinella
- University of Pittsburgh Medical CenterPittsburghPennsylvaniaUSA
| | - Maly Fenelus
- Memorial‐Sloan Kettering Medical CenterNew YorkNew YorkUSA
| | - Darla Liles
- East Carolina University Medical CenterGreenvilleNorth CarolinaUSA
| | | | | | | | | | | | - Pampee Young
- Vanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Andrew Johnson
- University of Minnesota Medical CenterMinneapolisMinnesotaUSA
| | | | | | | | - Elizabeth Malynn
- Harvard University – Beth Israel Deaconess HospitalBostonMassachusettsUSA
| | | | | | | | - Kathy Liu
- Cerus CorporationConcordCaliforniaUSA
| | | | | | | | | | | |
Collapse
|
6
|
Santa Maria F, Huang YJS, Vanlandingham DL, Bringmann P. Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies. Pathogens 2022; 11:pathogens11050521. [PMID: 35631042 PMCID: PMC9147860 DOI: 10.3390/pathogens11050521] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2022] [Revised: 04/24/2022] [Accepted: 04/25/2022] [Indexed: 12/04/2022] Open
Abstract
No cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transfusion-transmitted infections (TTI) have been reported. The detection of viral RNA in peripheral blood from infected patients and blood components from infected asymptomatic blood donors is, however, concerning. This study investigated the efficacy of the amotosalen/UVA light (A/UVA) and amustaline (S-303)/glutathione (GSH) pathogen reduction technologies (PRT) to inactivate SARS-CoV-2 in plasma and platelet concentrates (PC), or red blood cells (RBC), respectively. Plasma, PC prepared in platelet additive solution (PC-PAS) or 100% plasma (PC-100), and RBC prepared in AS-1 additive solution were spiked with SARS-CoV-2 and PR treated. Infectious viral titers were determined by plaque assay and log reduction factors (LRF) were determined by comparing titers before and after treatment. PR treatment of SARS-CoV-2-contaminated blood components resulted in inactivation of the infectious virus to the limit of detection with A/UVA LRF of >3.3 for plasma, >3.2 for PC-PAS-plasma, and >3.5 for PC-plasma and S-303/GSH LRF > 4.2 for RBC. These data confirm the susceptibility of coronaviruses, including SARS-CoV-2 to A/UVA treatment. This study demonstrates the effectiveness of the S-303/GSH treatment to inactivate SARS-CoV-2, and that PRT can reduce the risk of SARS-CoV-2 TTI in all blood components.
Collapse
Affiliation(s)
| | - Yan-Jang S. Huang
- Department of Diagnostic Medicine/Pathobiology, Biosecurity Research Institute, Kansas State University, Manhattan, KS 66506, USA; (Y.-J.S.H.); (D.L.V.)
| | - Dana L. Vanlandingham
- Department of Diagnostic Medicine/Pathobiology, Biosecurity Research Institute, Kansas State University, Manhattan, KS 66506, USA; (Y.-J.S.H.); (D.L.V.)
| | | |
Collapse
|
7
|
Saba B, Hasan SW, Kjellerup BV, Christy AD. Capacity of existing wastewater treatment plants to treat SARS-CoV-2. A review. BIORESOURCE TECHNOLOGY REPORTS 2021; 15:100737. [PMID: 34179735 PMCID: PMC8216935 DOI: 10.1016/j.biteb.2021.100737] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 06/12/2021] [Accepted: 06/12/2021] [Indexed: 12/16/2022]
Abstract
Water is one of many viral transmission routes, and the presence of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) in wastewater has brought attention to its treatment. SARS CoV-2 primarily transmits in the air but the persistence of the virus in the water possibly can serve as a secondary source even though current studies do not show this. In this paper, an evaluation of the current literature with regards to the treatment of SARS-CoV-2 in wastewater treatment plant (WWTP) effluents and biosolids is presented. Treatment efficiencies of WWTPs are compared for viral load reduction on the basis of publicly available data. The results of this evaluation indicate that existing WWTPs are effectively removing 1-6 log10 viable SARS-CoV-2. However, sludge and biosolids provide an umbrella of protection from treatment and inactivation to the virus. Hence, sludge treatment factors like high temperature, pH changes, and predatory microorganisms can effectively inactivate SARS-CoV-2.
Collapse
Affiliation(s)
- Beenish Saba
- Department of Food, Agricultural and Biological Engineering, The Ohio State University, 590 Woody Hayes Drive, Columbus, OH 43210, USA
- Department of Environmental Sciences, PMAS Arid Agriculture University Rawalpindi, 46300, Rawalpindi, Pakistan
| | - Shadi W Hasan
- Center for Membranes and Advanced Water Technology (CMAT), Department of Chemical Engineering, Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi, United Arab Emirates
| | - Birthe V Kjellerup
- Department of Civil and Environmental Engineering, University of Maryland at College Park, College Park, MD, USA
| | - Ann D Christy
- Department of Food, Agricultural and Biological Engineering, The Ohio State University, 590 Woody Hayes Drive, Columbus, OH 43210, USA
| |
Collapse
|
8
|
Hindawi SI, El-Kafrawy SA, Hassan AM, Badawi MA, Bayoumi MM, Almalki AA, Zowawi HM, Tolah AM, Alandijany TA, Abunada Q, Picard-Maureau M, Damanhouri GA, Azhar EI. Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet A light. Transfus Clin Biol 2021; 29:31-36. [PMID: 34411748 PMCID: PMC8366050 DOI: 10.1016/j.tracli.2021.08.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2021] [Revised: 08/06/2021] [Accepted: 08/12/2021] [Indexed: 12/11/2022]
Abstract
Objectives The detection of SARS-CoV-2 RNA in blood and platelet concentrates from asymptomatic donors, and the detection of viral particles on the surface and inside platelets during in vitro experiments, raised concerns over the potential risk for transfusion-transmitted-infection (TTI). The objective of this study was to assess the efficacy of the amotosalen/UVA pathogen reduction technology for SARS-CoV-2 in human platelet concentrates to mitigate such potential risk. Material and methods Five apheresis platelet units in 100% plasma were spiked with a clinical SARS-CoV-2 isolate followed by treatment with amotosalen/UVA (INTERCEPT Blood System), pre- and posttreatment samples were collected as well as untreated positive and negative controls. The infectious viral titer was assessed by plaque assay and the genomic titer by quantitative RT-PCR. To exclude the presence of infectious particles post-pathogen reduction treatment below the limit of detection, three consecutive rounds of passaging on permissive cell lines were conducted. Results SARS-CoV-2 in platelet concentrates was inactivated with amotosalen/UVA below the limit of detection with a mean log reduction of > 3.31 ± 0.23. During three consecutive rounds of passaging, no viral replication was detected. Pathogen reduction treatment also inhibited nucleic acid detection with a log reduction of > 4.46 ± 0.51 PFU equivalents. Conclusion SARS-CoV-2 was efficiently inactivated in platelet concentrates by amotosalen/UVA treatment. These results are in line with previous inactivation data for SARS-CoV-2 in plasma as well as MERS-CoV and SARS-CoV-1 in platelets and plasma, demonstrating efficient inactivation of human coronaviruses.
Collapse
Affiliation(s)
- S I Hindawi
- Department of Hematology, Blood Transfusion Services, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
| | - S A El-Kafrawy
- Special Infectious Agents Unit, BSL3, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - A M Hassan
- Special Infectious Agents Unit, BSL3, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - M A Badawi
- Department of Hematology, Blood Transfusion Services, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - M M Bayoumi
- Blood Transfusion Services, King Abdulaziz University Hospital, Jeddah 21589, Saudi Arabia
| | - A A Almalki
- Blood Transfusion Services, King Abdulaziz University Hospital, Jeddah 21589, Saudi Arabia
| | - H M Zowawi
- College of Medicine, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 3660, Riyadh 11481, Saudi Arabia
| | - A M Tolah
- Special Infectious Agents Unit, BSL3, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - T A Alandijany
- Special Infectious Agents Unit, BSL3, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Q Abunada
- Cerus Europe B.V., Stationsstraat 79-D, 3811 Amersfoort, The Netherlands
| | - M Picard-Maureau
- Cerus Europe B.V., Stationsstraat 79-D, 3811 Amersfoort, The Netherlands
| | - G A Damanhouri
- Department of Hematology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - E I Azhar
- Special Infectious Agents Unit, BSL3, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
| |
Collapse
|
9
|
Delabranche X, Kientz D, Tacquard C, Bertrand F, Roche A, Tran Ba Loc P, Humbrecht C, Sirlin F, Pivot X, Collange O, Levy F, Oulehri W, Gachet C, Mertes P. Impact of COVID-19 and lockdown regarding blood transfusion. Transfusion 2021; 61:2327-2335. [PMID: 34255374 PMCID: PMC8447413 DOI: 10.1111/trf.16422] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Revised: 03/10/2021] [Accepted: 03/10/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND The outbreak of a SARS-CoV-2 resulted in a massive afflux of patients in hospital and intensive care units with many challenges. Blood transfusion was one of them regarding both blood banks (safety, collection, and stocks) and consumption (usual care and unknown specific demand of COVID-19 patients). The risk of mismatch was sufficient to plan blood transfusion restrictions if stocks became limited. STUDY DESIGN AND METHODS Analyses of blood transfusion in a tertiary hospital and blood collection in the referring blood bank between February 24 and May 31, 2020. RESULTS Withdrawal of elective surgery and non-urgent care and admission of 2291 COVID-19 patients reduced global activity by 33% but transfusion by 17% only. Only 237 (10.3) % of COVID-19 patients required blood transfusion, including 45 (2.0%) with acute bleeding. Lockdown and cancellation of mobile collection resulted in an 11% reduction in blood donation compared to 2019. The ratio of reduction in blood transfusion to blood donation remained positive and stocks were slightly enhanced. DISCUSSION Reduction of admissions due to SARS-CoV-2 pandemic results only in a moderate decrease of blood transfusion. Incompressible blood transfusions concern urgent surgery, acute bleeding (including some patients with COVID-19, especially under high anticoagulation), or are supportive for chemotherapy-induced aplasia or chronic anemia. Lockdown results in a decrease of blood donation by cancellation of mobile donation but with little impact on a short period by mobilization of usual donors. No mismatch between demand and donation was evidenced and no planned restriction to blood transfusion was necessary.
Collapse
Affiliation(s)
- Xavier Delabranche
- Anaesthesia, Intensive Care and Perioperative Medicine, Nouvel Hôpital CivilStrasbourg University HospitalStrasbourgFrance
| | - Daniel Kientz
- Établissement Français du Sang Grand‐Est, site de StrasbourgStrasbourgFrance
| | - Charles Tacquard
- Anaesthesia, Intensive Care and Perioperative Medicine, Nouvel Hôpital CivilStrasbourg University HospitalStrasbourgFrance
- Établissement Français du Sang Grand‐Est, site de StrasbourgStrasbourgFrance
| | | | - Anne‐Claude Roche
- Anaesthesia, Intensive Care and Perioperative Medicine, Nouvel Hôpital CivilStrasbourg University HospitalStrasbourgFrance
| | - Pierre Tran Ba Loc
- Department for Medical InformationStrasbourg University HospitalStrasbourgFrance
| | - Catherine Humbrecht
- Établissement Français du Sang Grand‐Est, site de StrasbourgStrasbourgFrance
| | | | | | - Olivier Collange
- Anaesthesia, Intensive Care and Perioperative Medicine, Nouvel Hôpital CivilStrasbourg University HospitalStrasbourgFrance
| | - François Levy
- Anaesthesia, Intensive Care and Perioperative Medicine, Nouvel Hôpital CivilStrasbourg University HospitalStrasbourgFrance
- Transfusion MedicineStrasbourg University HospitalStrasbourgFrance
| | - Walid Oulehri
- Anaesthesia, Intensive Care and Perioperative Medicine, Nouvel Hôpital CivilStrasbourg University HospitalStrasbourgFrance
| | - Christian Gachet
- Établissement Français du Sang Grand‐Est, site de StrasbourgStrasbourgFrance
| | - Paul‐Michel Mertes
- Anaesthesia, Intensive Care and Perioperative Medicine, Nouvel Hôpital CivilStrasbourg University HospitalStrasbourgFrance
| |
Collapse
|
10
|
Li B, Wang W, Song W, Zhao Z, Tan Q, Zhao Z, Tang L, Zhu T, Yin J, Bai J, Dong X, Tan S, Hu Q, Tang BZ, Huang X. Antiviral and Anti‐Inflammatory Treatment with Multifunctional Alveolar Macrophage‐Like Nanoparticles in a Surrogate Mouse Model of COVID‐19. ADVANCED SCIENCE 2021; 8:2003556. [PMCID: PMC8209923 DOI: 10.1002/advs.202003556] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
The pandemic of coronavirus disease 2019 (COVID‐19) is continually worsening. Clinical treatment for COVID‐19 remains primarily supportive with no specific medicines or regimens. Here, the development of multifunctional alveolar macrophage (AM)‐like nanoparticles (NPs) with photothermal inactivation capability for COVID‐19 treatment is reported. The NPs, made by wrapping polymeric cores with AM membranes, display the same surface receptors as AMs, including the coronavirus receptor and multiple cytokine receptors. By acting as AM decoys, the NPs block coronavirus from host cell entry and absorb various proinflammatory cytokines, thus achieving combined antiviral and anti‐inflammatory treatment. To enhance the antiviral efficiency, an efficient photothermal material based on aggregation‐induced emission luminogens is doped into the NPs for virus photothermal disruption under near‐infrared (NIR) irradiation. In a surrogate mouse model of COVID‐19 caused by murine coronavirus, treatment with multifunctional AM‐like NPs with NIR irradiation decreases virus burden and cytokine levels, reduces lung damage and inflammation, and confers a significant survival advantage to the infected mice. Crucially, this therapeutic strategy may be clinically applied for the treatment of COVID‐19 at early stage through atomization inhalation of the NPs followed by NIR irradiation of the respiratory tract, thus alleviating infection progression and reducing transmission risk.
Collapse
Affiliation(s)
- Bin Li
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| | - Wei Wang
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Engineering Research Center of Tibetan Medicine Detection Technology, Ministry of EducationXizang Minzu UniversityXianyangShaanxi712082China
| | - Weifeng Song
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
| | - Zheng Zhao
- Department of ChemistryThe Hong Kong University of Science and TechnologyClear Water BayKowloonHong Kong999077China
| | - Qingqin Tan
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| | - Zhaoyan Zhao
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| | - Lantian Tang
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| | - Tianchuan Zhu
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| | - Jialing Yin
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| | - Jun Bai
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| | - Xin Dong
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| | - Siyi Tan
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| | - Qunying Hu
- Engineering Research Center of Tibetan Medicine Detection Technology, Ministry of EducationXizang Minzu UniversityXianyangShaanxi712082China
| | - Ben Zhong Tang
- Department of ChemistryThe Hong Kong University of Science and TechnologyClear Water BayKowloonHong Kong999077China
| | - Xi Huang
- Center for Infection and ImmunityGuangdong Provincial Key Laboratory of Biomedical ImagingThe Fifth Affiliated Hospital of Sun Yat‐sen UniversityZhuhaiGuangdong519000China
- Southern Marine Science and Engineering Guangdong LaboratoryZhuhaiGuangdong519000China
| |
Collapse
|
11
|
Kostin AI, Lundgren MN, Bulanov AY, Ladygina EA, Chirkova KS, Gintsburg AL, Logunov DY, Dolzhikova IV, Shcheblyakov DV, Borovkova NV, Godkov MA, Bazhenov AI, Shustov VV, Bogdanova AS, Kamalova AR, Ganchin VV, Dombrovskiy EA, Volkov SE, Drozdova NE, Petrikov SS. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma. Vox Sang 2021; 116:665-672. [PMID: 33734455 PMCID: PMC8250394 DOI: 10.1111/vox.13056] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 11/28/2020] [Accepted: 11/29/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND AND OBJECTIVES COVID-19 convalescent plasma is an experimental treatment against SARS-CoV-2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS-CoV2 in convalescent plasma. MATERIALS AND METHODS A total of 140 plasma doses collected by plasmapheresis from COVID-19 convalescent donors were subjected to pathogen reduction by three methods: methylene blue (M)/visible light, riboflavin (R)/UVB and amotosalen (A)/UVA. To conduct a paired comparison, individual plasma doses were divided into 2 samples that were subjected to one of these methods. The titres of SARS-CoV2 neutralizing antibodies (NtAbs) and levels of specific immunoglobulins to RBD, S- and N-proteins of SARS-CoV-2 were measured before and after pathogen reduction. RESULTS The methods reduced NtAbs titres differently: among units with the initial titre 80 or above, 81% of units remained unchanged and 19% decreased by one step after methylene blue; 60% were unchanged and 40% decreased by one step after amotosalen; after riboflavin 43% were unchanged and 50% (7%, respectively) had a one-step (two-step, respectively) decrease. Paired two-sample comparisons (M vs. A, M vs. R and A vs. R) revealed that the largest statistically significant decrease in quantity and activity of the specific antibodies resulted from the riboflavin treatment. CONCLUSION Pathogen reduction with methylene blue or with amotosalen provides the greater likelihood of preserving the immunological properties of the COVID-19 convalescent plasma compared to riboflavin.
Collapse
Affiliation(s)
- Alexander I Kostin
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Maria N Lundgren
- Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden
| | - Andrey Y Bulanov
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Elena A Ladygina
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Karina S Chirkova
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Alexander L Gintsburg
- The Federal State Budgetary Institution 'National Research Center of Epidemiology and Microbiology N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Denis Y Logunov
- The Federal State Budgetary Institution 'National Research Center of Epidemiology and Microbiology N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Inna V Dolzhikova
- The Federal State Budgetary Institution 'National Research Center of Epidemiology and Microbiology N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Dmitry V Shcheblyakov
- The Federal State Budgetary Institution 'National Research Center of Epidemiology and Microbiology N.F. Gamaleya' of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Natalia V Borovkova
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Mikhail A Godkov
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Alexey I Bazhenov
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Valeriy V Shustov
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Alina S Bogdanova
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Alina R Kamalova
- Healthcare Ministry of Russia, N.I. Pirogov Federal Russian National Research Medical University, Moscow, Russia
| | - Vladimir V Ganchin
- Autonomous Non-Commercial Organization «Center of Analytical Development of the Social Sector», Moscow, Russia
| | - Eugene A Dombrovskiy
- Autonomous Non-Commercial Organization «Center of Analytical Development of the Social Sector», Moscow, Russia
| | | | - Nataliya E Drozdova
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| | - Sergey S Petrikov
- Moscow Department of Healthcare, N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russia
| |
Collapse
|
12
|
Wasiluk T, Rogowska A, Boczkowska-Radziwon B, Zebrowska A, Bolkun L, Piszcz J, Radziwon P. Maintaining plasma quality and safety in the state of ongoing epidemic - The role of pathogen reduction. Transfus Apher Sci 2021; 60:102953. [PMID: 33023853 PMCID: PMC7832281 DOI: 10.1016/j.transci.2020.102953] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 09/01/2020] [Accepted: 09/02/2020] [Indexed: 01/22/2023]
Abstract
In the field of transfusion medicine, many pathogen reduction techniques (PRTs) are currently available, including those based on photochemical (PI) and photodynamic inactivation (PDI). This is particularly important in the face of emerging viral pathogens that may pose a threat to blood recipients, as in the case of the COVID-19 pandemic. However, PRTs have some limitations, primarily related to their adverse effects on coagulation factors, which should be considered before their intended use. A comprehensive search of PubMed, Wiley Online Library and Science Direct databases was conducted to identify original papers. As a result, ten studies evaluating fresh plasma and frozen-thawed plasma treated with different PI/ PDI methods and evaluating concentrations of coagulation factors and natural anticoagulants both before and after photochemical treatment were included in the review. The use of PI and PDI is associated with a significant decrease in the activity of all analysed coagulation factors, while the recovery of natural anticoagulants remains at a satisfactory level, variable for individual inactivation methods. In addition, the published evidence reviewed above does not unequivocally favour the implementation of PI/PDI either before freezing or after thawing as plasma products obtained with these two approaches seem to satisfy the existing quality criteria. Based on current evidence, if implemented responsibly and in accordance with the current guidelines, both PI and PDI can ensure satisfactory plasma quality and improve its safety.
Collapse
Affiliation(s)
- Tomasz Wasiluk
- Regional Centre for Transfusion Medicine, Bialystok, Poland.
| | - Anna Rogowska
- Regional Centre for Transfusion Medicine, Bialystok, Poland
| | | | | | - Lukasz Bolkun
- Department of Haematology, Medical University of Bialystok, Bialystok, Poland
| | - Jaroslaw Piszcz
- Department of Haematology, Medical University of Bialystok, Bialystok, Poland
| | - Piotr Radziwon
- Regional Centre for Transfusion Medicine, Bialystok, Poland; Department of Haematology, Medical University of Bialystok, Bialystok, Poland
| |
Collapse
|
13
|
Sah R, Rodriguez-Morales AJ, Fathah Z, Shrestha S, Mehta R, Khatiwada AP, Tiwari R, Sharun K, Mohapatra RK, Dhawan M, Emran TB, Dhama K. Blood scarcity at the blood banks during COVID-19 pandemic and strategies to promote blood donations: current knowledge and futuristic vision. EGYPTIAN JOURNAL OF BASIC AND APPLIED SCIENCES 2021; 8:261-268. [DOI: 10.1080/2314808x.2021.1966580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 08/07/2021] [Indexed: 09/01/2023]
Affiliation(s)
- Ranjit Sah
- Tribhuvan University Teaching Hospital, Institute Of Medicine, Kathmandu, Nepal
- National Public Health Laboratory, Kathmandu, Nepal
| | - Alfonso J. Rodriguez-Morales
- Grupo De Investigación Biomedicina, Faculty Of Medicine, Fundacion Universitaria Autonoma De Las Americas, Pereira, Risaralda, Colombia
- School Of Medicine, Universidad Privada Franz Tamayo (Unifranz), Cochabamba, Bolivia
| | | | - Sunil Shrestha
- Department Of Pharmaceutical And Health Service Research, Nepal Health Research And Innovation Foundation, Lalitpur, Nepal
| | | | - Asmita Priyadarshini Khatiwada
- Department Of Pharmaceutical And Health Service Research, Nepal Health Research And Innovation Foundation, Lalitpur, Nepal
| | - Ruchi Tiwari
- Department Of Veterinary Microbiology And Immunology, College Of Veterinary Sciences, Uttar Pradesh Pandit DeenDayal Upadhyaya PashuChikitsa Vigyan Vishwavidyalaya Evam Go AnusandhanSansthan (DUVASU), Mathura, India
| | - Khan Sharun
- Division Of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - Ranjan K Mohapatra
- Department Of Chemistry, Government College Of Engineering, Keonjhar, Odisha, India
| | - Manish Dhawan
- Department Of Microbiology, Punjab Agricultural University, Ludhiana, India
- The Trafford Group Of Colleges, Manchester, UK
| | - Talha Bin Emran
- Department Of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh
| | - Kuldeep Dhama
- Division Of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| |
Collapse
|
14
|
Azhar EI, Hindawi SI, El-Kafrawy SA, Hassan AM, Tolah AM, Alandijany TA, Bajrai LH, Damanhouri GA. Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma. Vox Sang 2020; 116:673-681. [PMID: 33277935 PMCID: PMC8359189 DOI: 10.1111/vox.13043] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2020] [Revised: 11/13/2020] [Accepted: 11/15/2020] [Indexed: 12/11/2022]
Abstract
Background and objectives During the ongoing pandemic of COVID‐19, SARS‐CoV‐2 RNA was detected in plasma and platelet products from asymptomatic blood donors, raising concerns about potential risk of transfusion transmission, also in the context of the current therapeutic approach utilizing plasma from convalescent donors. The objective of this study was to assess the efficacy of amotosalen/UVA light treatment to inactivate SARS‐CoV‐2 in human plasma to reduce the risk of potential transmission through blood transfusion. Methods Pools of three whole‐blood‐derived human plasma units (630–650 ml) were inoculated with a clinical SARS‐CoV‐2 isolate. Spiked units were treated with amotosalen/UVA light (INTERCEPT Blood System™) to inactivate SARS‐CoV‐2. Infectious titres and genomic viral load were assessed by plaque assay and real‐time quantitative PCR. Inactivated samples were subject to three successive passages on permissive tissue culture to exclude the presence of replication‐competent viral particles. Results Inactivation of infectious viral particles in spiked plasma units below the limit of detection was achieved by amotosalen/UVA light treatment with a mean log reduction of >3·32 ± 0·2. Passaging of inactivated samples on permissive tissue showed no viral replication even after 9 days of incubation and three passages, confirming complete inactivation. The treatment also inhibited NAT detection by nucleic acid modification with a mean log reduction of 2·92 ± 0·87 PFU genomic equivalents. Conclusion Amotosalen/UVA light treatment of SARS‐CoV‐2 spiked human plasma units efficiently and completely inactivated >3·32 ± 0·2 log of SARS‐CoV‐2 infectivity, showing that such treatment could minimize the risk of transfusion‐related SARS‐CoV‐2 transmission.
Collapse
Affiliation(s)
- Esam I Azhar
- Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.,Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Salwa I Hindawi
- Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.,Department of Hematology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Sherif A El-Kafrawy
- Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.,Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Ahmed M Hassan
- Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Ahmed M Tolah
- Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.,Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Thamir A Alandijany
- Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.,Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Leena H Bajrai
- Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.,Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Ghazi A Damanhouri
- Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.,Department of Hematology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| |
Collapse
|
15
|
Varma SR, Jaber M, Abu Fanas S, Desai V, Thomas S, Khair M. Pathogen Reduction Technology: A Novel Possibility for Inactivation of Blood Products Used in Oral and Periodontal Surgeries. J Int Soc Prev Community Dent 2020; 10:713-718. [PMID: 33437703 PMCID: PMC7791590 DOI: 10.4103/jispcd.jispcd_327_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Revised: 09/01/2020] [Accepted: 09/15/2020] [Indexed: 11/04/2022] Open
Abstract
Emergency surgical treatment has been challenging and the risk of blood contamination has been high, which is a concern among the medical and dental fraternity. The risk outweighs the benefits in these unprecedented times if proper screening and inactivation of blood products are not performed. Pathogen reduction technologies incorporate various modalities for the inactivation of blood products mainly related to blood transfusion. Oral surgical procedures and periodontal surgeries use platelet-rich fibrin for various regenerative procedures that amplify the prognosis positively. The use of blood products for various treatments could result in contamination, a factor which should be significant attention. The objective of this study was to review the role of pathogen reduction technology in inactivating pathogens in blood products and its use in oral and periodontal surgical procedures. The literature presented in the study is from original studies from a period of 2000 to 2020 which was sourced from Medline, PubMed, and Cochrane central databases. Relevant published papers and in-press papers that provided information were identified and selected. The studies presented have shown data related to implementation of pathogen reduction technologies in relation to the severe acute respiratory syndrome, Middle East respiratory syndrome, and its possible implementation in coronavirus disease-2019 (COVID-19). The paper reviews the various technologies offered and the possibility to eradicate pathogens found in routine blood products, used in oral and periodontal surgical procedures. In all probability, the use of pathogen reduction technology might offer a ray of light to contain the spread among dental treatment procedures.
Collapse
Affiliation(s)
- Sudhir Rama Varma
- Department of Clinical Sciences, College of Dentistry, Ajman University, Ajman, UAE
| | - Mohamed Jaber
- Department of Clinical Sciences, College of Dentistry, Ajman University, Ajman, UAE
| | - Salem Abu Fanas
- Department of Clinical Sciences, College of Dentistry, Ajman University, Ajman, UAE
| | - Vijay Desai
- Department of Clinical Sciences, College of Dentistry, Ajman University, Ajman, UAE
| | - Sam Thomas
- Department of Oral and Maxillofacial Surgery, College of Dentistry, Ajman University, Ajman, UAE
| | - Moutassem Khair
- Department of Basic Sciences, College of Dentistry, Ajman University, Ajman, UAE
| |
Collapse
|
16
|
Hanna R, Dalvi S, Sălăgean T, Bordea IR, Benedicenti S. Phototherapy as a Rational Antioxidant Treatment Modality in COVID-19 Management; New Concept and Strategic Approach: Critical Review. Antioxidants (Basel) 2020; 9:E875. [PMID: 32947974 PMCID: PMC7555229 DOI: 10.3390/antiox9090875] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 09/11/2020] [Accepted: 09/13/2020] [Indexed: 12/11/2022] Open
Abstract
The COVID-19 pandemic has taken the entire globe by storm. The pathogenesis of this virus has shown a cytokine storm release, which contributes to critical or severe multi-organ failure. Currently the ultimate treatment is palliative; however, many modalities have been introduced with effective or minimal outcomes. Meanwhile, enormous efforts are ongoing to produce safe vaccines and therapies. Phototherapy has a wide range of clinical applications against various maladies. This necessitates the exploration of the role of phototherapy, if any, for COVID-19. This critical review was conducted to understand COVID-19 disease and highlights the prevailing facts that link phototherapy utilisation as a potential treatment modality for SARS-CoV-2 viral infection. The results demonstrated phototherapy's efficacy in regulating cytokines and inflammatory mediators, increasing angiogenesis and enhancing healing in chronic pulmonary inflammatory diseases. In conclusion, this review answered the following research question. Which molecular and cellular mechanisms of action of phototherapy have demonstrated great potential in enhancing the immune response and reducing host-viral interaction in COVID-19 patients? Therefore, phototherapy is a promising treatment modality, which needs to be validated further for COVID-19 by robust and rigorous randomised, double blind, placebo-controlled, clinical trials to evaluate its impartial outcomes and safety.
Collapse
Affiliation(s)
- Reem Hanna
- Department of Surgical Sciences and Integrated Diagnostics, Laser Therapy Centre, University of Genoa, Viale Benedetto XV,6, 16132 Genoa, Italy; (S.D.); (S.B.)
- Department of Oral Surgery, Dental Institute, King’s College Hospital NHS Foundation Trust, London SE5 9RS, UK
| | - Snehal Dalvi
- Department of Surgical Sciences and Integrated Diagnostics, Laser Therapy Centre, University of Genoa, Viale Benedetto XV,6, 16132 Genoa, Italy; (S.D.); (S.B.)
- Department of Periodontology, Swargiya Dadasaheb Kalmegh Smruti Dental College and Hospital, Nagpur 441110, India
| | - Tudor Sălăgean
- Department of Land Measurements and Exact Sciences, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, 400372 Cluj-Napoca, Romania
| | - Ioana Roxana Bordea
- Department of Oral Rehabilitation, “Iuliu Hațieganu” University of Medicine and Pharmacy Cluj-Napoca, 400012 Cluj-Napoca, Romania;
| | - Stefano Benedicenti
- Department of Surgical Sciences and Integrated Diagnostics, Laser Therapy Centre, University of Genoa, Viale Benedetto XV,6, 16132 Genoa, Italy; (S.D.); (S.B.)
| |
Collapse
|
17
|
Hadi J, Dunowska M, Wu S, Brightwell G. Control Measures for SARS-CoV-2: A Review on Light-Based Inactivation of Single-Stranded RNA Viruses. Pathogens 2020; 9:E737. [PMID: 32911671 PMCID: PMC7558314 DOI: 10.3390/pathogens9090737] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 09/04/2020] [Accepted: 09/05/2020] [Indexed: 12/20/2022] Open
Abstract
SARS-CoV-2 is a single-stranded RNA virus classified in the family Coronaviridae. In this review, we summarize the literature on light-based (UV, blue, and red lights) sanitization methods for the inactivation of ssRNA viruses in different matrixes (air, liquid, and solid). The rate of inactivation of ssRNA viruses in liquid was higher than in air, whereas inactivation on solid surfaces varied with the type of surface. The efficacy of light-based inactivation was reduced by the presence of absorptive materials. Several technologies can be used to deliver light, including mercury lamp (conventional UV), excimer lamp (UV), pulsed-light, and light-emitting diode (LED). Pulsed-light technologies could inactivate viruses more quickly than conventional UV-C lamps. Large-scale use of germicidal LED is dependent on future improvements in their energy efficiency. Blue light possesses virucidal potential in the presence of exogenous photosensitizers, although femtosecond laser (ultrashort pulses) can be used to circumvent the need for photosensitizers. Red light can be combined with methylene blue for application in medical settings, especially for sanitization of blood products. Future modelling studies are required to establish clearer parameters for assessing susceptibility of viruses to light-based inactivation. There is considerable scope for improvement in the current germicidal light-based technologies and practices.
Collapse
Affiliation(s)
- Joshua Hadi
- AgResearch Ltd., Hopkirk Research Institute, Cnr University Ave and Library Road, Massey University, Palmerston North 4442, New Zealand; (J.H.); (S.W.)
| | - Magdalena Dunowska
- School of Veterinary Science, Massey University Manawatu (Turitea) Tennent Drive, Palmerston North 4474, New Zealand;
| | - Shuyan Wu
- AgResearch Ltd., Hopkirk Research Institute, Cnr University Ave and Library Road, Massey University, Palmerston North 4442, New Zealand; (J.H.); (S.W.)
| | - Gale Brightwell
- AgResearch Ltd., Hopkirk Research Institute, Cnr University Ave and Library Road, Massey University, Palmerston North 4442, New Zealand; (J.H.); (S.W.)
- New Zealand Food Safety Science and Research Centre, Massey University Manawatu (Turitea) Tennent Drive, Palmerston North 4474, New Zealand
| |
Collapse
|
18
|
Bloch EM, Goel R, Wendel S, Burnouf T, Al-Riyami AZ, Ang AL, DeAngelis V, Dumont LJ, Land K, Lee CK, Oreh A, Patidar G, Spitalnik SL, Vermeulen M, Hindawi S, Van den Berg K, Tiberghien P, Vrielink H, Young P, Devine D, So-Osman C. Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries. Vox Sang 2020; 116:18-35. [PMID: 32533868 PMCID: PMC7323328 DOI: 10.1111/vox.12970] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 06/08/2020] [Accepted: 06/08/2020] [Indexed: 12/11/2022]
Abstract
Background and objectives COVID‐19 convalescent plasma (CCP) has been used, predominantly in high‐income countries (HICs) to treat COVID‐19; available data suggest the safety and efficacy of use. We sought to develop guidance for procurement and use of CCP, particularly in low‐ and middle‐income countries (LMICs) for which data are lacking. Materials and methods A multidisciplinary, geographically representative group of individuals with expertise spanning transfusion medicine, infectious diseases and haematology was tasked with the development of a guidance document for CCP, drawing on expert opinion, survey of group members and review of available evidence. Three subgroups (i.e. donor, product and patient) were established based on self‐identified expertise and interest. Here, the donor and product‐related challenges are summarized and contrasted between HICs and LMICs with a view to guide related practices. Results The challenges to advance CCP therapy are different between HICs and LMICs. Early challenges in HICs related to recruitment and qualification of sufficient donors to meet the growing demand. Antibody testing also posed a specific obstacle given lack of standardization, variable performance of the assays in use and uncertain interpretation of results. In LMICs, an extant transfusion deficit, suboptimal models of donor recruitment (e.g. reliance on replacement and paid donors), limited laboratory capacity for pre‐donation qualification and operational considerations could impede wide adoption. Conclusion There has been wide‐scale adoption of CCP in many HICs, which could increase if clinical trials show efficacy of use. By contrast, LMICs, having received little attention, require locally applicable strategies for adoption of CCP.
Collapse
Affiliation(s)
- Evan M Bloch
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Ruchika Goel
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and Mississippi Valley Regional Blood Center, Springfield, Illinois, USA
| | | | - Thierry Burnouf
- Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.,International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
| | - Arwa Z Al-Riyami
- Department of Hematology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman
| | - Ai Leen Ang
- Blood Services Group, Health Sciences Authority, Singapore, Singapore
| | | | - Larry J Dumont
- Vitalant Research Institute, Denver, CO, USA.,University of Colorado School of Medicine, Denver, CO, USA.,Geisel School of Medicine at Dartmouth, Lebanon, NH, USA
| | - Kevin Land
- Vice President Clinical Services, Vitalant, Scottsdale, AZ, USA.,Department of Pathology, UT Health Science Center San Antonio, San Antonio, TX, USA
| | - Cheuk-Kwong Lee
- Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China, China.,King's Park Rise, Kowloon, China
| | - Adaeze Oreh
- National Blood Transfusion Service, Department of Hospital Services, Federal Ministry of Health, Abuja, Nigeria
| | - Gopal Patidar
- Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India
| | - Steven L Spitalnik
- Department of Pathology & Cell Biology, Columbia University, New York, NY, USA
| | - Marion Vermeulen
- The South African National Blood Service, Johannesbur, South Africa
| | - Salwa Hindawi
- Haematology & Transfusion Medicine, King Abdalaziz University, Jeddah, Saudi Arabia
| | | | | | - Hans Vrielink
- Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL, Netherlands
| | | | - Dana Devine
- Canadian Blood Services, Vancouver, BC, Canada.,Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Cynthia So-Osman
- Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL, Netherlands.,Department of Haematology, Erasmus Medical Center, Rotterdam, NL, Netherlands
| |
Collapse
|
19
|
Unger S, Christie-Holmes N, Guvenc F, Budylowski P, Mubareka S, Gray-Owen SD, O'Connor DL. Holder pasteurization of donated human milk is effective in inactivating SARS-CoV-2. CMAJ 2020; 192:E871-E874. [PMID: 32646870 DOI: 10.1503/cmaj.201309] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/30/2020] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Provision of pasteurized donor human milk, as a bridge to mother's own milk, is the standard of care for very low-birth-weight infants in hospital. The aim of this research was to confirm that Holder pasteurization (62.5°C for 30 min) would be sufficient to inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in donated human milk samples. METHODS We spiked frozen milk samples from 10 donors to the Rogers Hixon Ontario Human Milk Bank with SARS-CoV-2 to achieve a final concentration of 1 × 107 TCID50/mL (50% of the tissue culture infectivity dose per mL). We pasteurized samples using the Holder method or held them at room temperature for 30 minutes and plated serial dilutions on Vero E6 cells for 5 days. We included comparative controls in the study using milk samples from the same donors without addition of virus (pasteurized and unpasteurized) as well as replicates of Vero E6 cells directly inoculated with SARS-CoV-2. We reported cytopathic effects as TCID50/mL. RESULTS We detected no cytopathic activity in any of the SARS-CoV-2-spiked milk samples that had been pasteurized using the Holder method. In the SARS-CoV-2-spiked milk samples that were not pasteurized but were kept at room temperature for 30 minutes, we observed a reduction in infectious viral titre of about 1 log. INTERPRETATION Pasteurization of human milk by the Holder method (62.5°C for 30 min) inactivates SARS-CoV-2. Thus, in the event that donated human milk contains SARS-CoV-2 by transmission through the mammary gland or by contamination, this method of pasteurization renders milk safe for consumption and handling by care providers.
Collapse
Affiliation(s)
- Sharon Unger
- Rogers Hixon Ontario Human Milk Bank (Unger, O'Connor); Department of Paediatrics, Sinai Health (Unger); Combined Containment Level 3 Unit (Christie-Holmes, Guvenc, Budylowski, Gray-Owen), Departments of Molecular Genetics (Guvenc, Gray-Owen), Laboratory Medicine and Pathobiology (Mubareka), and Nutritional Sciences (O'Connor), and the Institute of Medical Sciences (Budylowski), University of Toronto; Sunnybrook Research Institute (Mubareka), Toronto, Ont.
| | - Natasha Christie-Holmes
- Rogers Hixon Ontario Human Milk Bank (Unger, O'Connor); Department of Paediatrics, Sinai Health (Unger); Combined Containment Level 3 Unit (Christie-Holmes, Guvenc, Budylowski, Gray-Owen), Departments of Molecular Genetics (Guvenc, Gray-Owen), Laboratory Medicine and Pathobiology (Mubareka), and Nutritional Sciences (O'Connor), and the Institute of Medical Sciences (Budylowski), University of Toronto; Sunnybrook Research Institute (Mubareka), Toronto, Ont
| | - Furkan Guvenc
- Rogers Hixon Ontario Human Milk Bank (Unger, O'Connor); Department of Paediatrics, Sinai Health (Unger); Combined Containment Level 3 Unit (Christie-Holmes, Guvenc, Budylowski, Gray-Owen), Departments of Molecular Genetics (Guvenc, Gray-Owen), Laboratory Medicine and Pathobiology (Mubareka), and Nutritional Sciences (O'Connor), and the Institute of Medical Sciences (Budylowski), University of Toronto; Sunnybrook Research Institute (Mubareka), Toronto, Ont
| | - Patrick Budylowski
- Rogers Hixon Ontario Human Milk Bank (Unger, O'Connor); Department of Paediatrics, Sinai Health (Unger); Combined Containment Level 3 Unit (Christie-Holmes, Guvenc, Budylowski, Gray-Owen), Departments of Molecular Genetics (Guvenc, Gray-Owen), Laboratory Medicine and Pathobiology (Mubareka), and Nutritional Sciences (O'Connor), and the Institute of Medical Sciences (Budylowski), University of Toronto; Sunnybrook Research Institute (Mubareka), Toronto, Ont
| | - Samira Mubareka
- Rogers Hixon Ontario Human Milk Bank (Unger, O'Connor); Department of Paediatrics, Sinai Health (Unger); Combined Containment Level 3 Unit (Christie-Holmes, Guvenc, Budylowski, Gray-Owen), Departments of Molecular Genetics (Guvenc, Gray-Owen), Laboratory Medicine and Pathobiology (Mubareka), and Nutritional Sciences (O'Connor), and the Institute of Medical Sciences (Budylowski), University of Toronto; Sunnybrook Research Institute (Mubareka), Toronto, Ont
| | - Scott D Gray-Owen
- Rogers Hixon Ontario Human Milk Bank (Unger, O'Connor); Department of Paediatrics, Sinai Health (Unger); Combined Containment Level 3 Unit (Christie-Holmes, Guvenc, Budylowski, Gray-Owen), Departments of Molecular Genetics (Guvenc, Gray-Owen), Laboratory Medicine and Pathobiology (Mubareka), and Nutritional Sciences (O'Connor), and the Institute of Medical Sciences (Budylowski), University of Toronto; Sunnybrook Research Institute (Mubareka), Toronto, Ont
| | - Deborah L O'Connor
- Rogers Hixon Ontario Human Milk Bank (Unger, O'Connor); Department of Paediatrics, Sinai Health (Unger); Combined Containment Level 3 Unit (Christie-Holmes, Guvenc, Budylowski, Gray-Owen), Departments of Molecular Genetics (Guvenc, Gray-Owen), Laboratory Medicine and Pathobiology (Mubareka), and Nutritional Sciences (O'Connor), and the Institute of Medical Sciences (Budylowski), University of Toronto; Sunnybrook Research Institute (Mubareka), Toronto, Ont
| |
Collapse
|
20
|
Abstract
: SARS-CoV-2 is a novel infectious agent that rapidly spread from a single city in China to all parts of the world. Right now, the world is facing a major pandemic crisis and every infected patient can infect the other two to three persons. The non-specific symptoms at the early stages of coronavirus 2019 (Covid-19) and also the presence of infected asymptomatic patients result in the absence of accurate estimation of infected patients. Although coronaviruses often affect the upper or lower respiratory tract, viral shedding in plasma or serum can occur and therefore, there is a theoretical risk regarding the transmission of these viruses by transfusion. Experience with other viruses from the corona family group (SARS-CoV and MERS-CoV) tells us that Covid-19 might have a significant impact on blood supply. Until now, SARS-CoV-2 has not been identified as a transfusion transmissible virus and viremia has only been diagnosed in serious patients who would not be allowed for blood donation. In this review article, the safety of blood products during the Covid-19 outbreak is discussed.
Collapse
|
21
|
Stawicki SP, Jeanmonod R, Miller AC, Paladino L, Gaieski DF, Yaffee AQ, De Wulf A, Grover J, Papadimos TJ, Bloem C, Galwankar SC, Chauhan V, Firstenberg MS, Di Somma S, Jeanmonod D, Garg SM, Tucci V, Anderson HL, Fatimah L, Worlton TJ, Dubhashi SP, Glaze KS, Sinha S, Opara IN, Yellapu V, Kelkar D, El-Menyar A, Krishnan V, Venkataramanaiah S, Leyfman Y, Saoud Al Thani HA, WB Nanayakkara P, Nanda S, Cioè-Peña E, Sardesai I, Chandra S, Munasinghe A, Dutta V, Dal Ponte ST, Izurieta R, Asensio JA, Garg M. The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper. J Glob Infect Dis 2020; 12:47-93. [PMID: 32773996 PMCID: PMC7384689 DOI: 10.4103/jgid.jgid_86_20] [Citation(s) in RCA: 186] [Impact Index Per Article: 46.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 04/25/2020] [Accepted: 05/04/2020] [Indexed: 02/06/2023] Open
Abstract
What started as a cluster of patients with a mysterious respiratory illness in Wuhan, China, in December 2019, was later determined to be coronavirus disease 2019 (COVID-19). The pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel Betacoronavirus, was subsequently isolated as the causative agent. SARS-CoV-2 is transmitted by respiratory droplets and fomites and presents clinically with fever, fatigue, myalgias, conjunctivitis, anosmia, dysgeusia, sore throat, nasal congestion, cough, dyspnea, nausea, vomiting, and/or diarrhea. In most critical cases, symptoms can escalate into acute respiratory distress syndrome accompanied by a runaway inflammatory cytokine response and multiorgan failure. As of this article's publication date, COVID-19 has spread to approximately 200 countries and territories, with over 4.3 million infections and more than 290,000 deaths as it has escalated into a global pandemic. Public health concerns mount as the situation evolves with an increasing number of infection hotspots around the globe. New information about the virus is emerging just as rapidly. This has led to the prompt development of clinical patient risk stratification tools to aid in determining the need for testing, isolation, monitoring, ventilator support, and disposition. COVID-19 spread is rapid, including imported cases in travelers, cases among close contacts of known infected individuals, and community-acquired cases without a readily identifiable source of infection. Critical shortages of personal protective equipment and ventilators are compounding the stress on overburdened healthcare systems. The continued challenges of social distancing, containment, isolation, and surge capacity in already stressed hospitals, clinics, and emergency departments have led to a swell in technologically-assisted care delivery strategies, such as telemedicine and web-based triage. As the race to develop an effective vaccine intensifies, several clinical trials of antivirals and immune modulators are underway, though no reliable COVID-19-specific therapeutics (inclusive of some potentially effective single and multi-drug regimens) have been identified as of yet. With many nations and regions declaring a state of emergency, unprecedented quarantine, social distancing, and border closing efforts are underway. Implementation of social and physical isolation measures has caused sudden and profound economic hardship, with marked decreases in global trade and local small business activity alike, and full ramifications likely yet to be felt. Current state-of-science, mitigation strategies, possible therapies, ethical considerations for healthcare workers and policymakers, as well as lessons learned for this evolving global threat and the eventual return to a "new normal" are discussed in this article.
Collapse
Affiliation(s)
- Stanislaw P Stawicki
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA,COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA,Address for correspondence: Dr. Stanislaw P Stawicki, Department of Research and Innovation, St. Luke's University Health Network, 801 Ostrum Street, Bethlehem, Pennsylvania, USA. E-mail:
| | - Rebecca Jeanmonod
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA,COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Andrew C Miller
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Lorenzo Paladino
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA,COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - David F Gaieski
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Anna Q Yaffee
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Annelies De Wulf
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Joydeep Grover
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Thomas J. Papadimos
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Christina Bloem
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Sagar C Galwankar
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA,COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Vivek Chauhan
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Michael S. Firstenberg
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA,COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Salvatore Di Somma
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Donald Jeanmonod
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA,COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Sona M Garg
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Veronica Tucci
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Harry L Anderson
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA,COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Lateef Fatimah
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Tamara J Worlton
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | | | - Krystal S Glaze
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Sagar Sinha
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Ijeoma Nnodim Opara
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Vikas Yellapu
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Dhanashree Kelkar
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Ayman El-Menyar
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Vimal Krishnan
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - S Venkataramanaiah
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Yan Leyfman
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | | | | | - Sudip Nanda
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Eric Cioè-Peña
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Indrani Sardesai
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Shruti Chandra
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Aruna Munasinghe
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Vibha Dutta
- COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Silvana Teixeira Dal Ponte
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Ricardo Izurieta
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA
| | - Juan A Asensio
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA,COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| | - Manish Garg
- Working Group on International Health Security, The American College of Academic International Academic Medicine, USA,COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA
| |
Collapse
|
22
|
Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang 2020; 115:488-494. [PMID: 32240545 DOI: 10.1111/vox.12926] [Citation(s) in RCA: 111] [Impact Index Per Article: 27.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2020] [Accepted: 03/28/2020] [Indexed: 01/08/2023]
Abstract
Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.
Collapse
Affiliation(s)
- Pierre Tiberghien
- Etablissement Français du Sang, La Plaine-St Denis, France.,UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France
| | - Xavier de Lamballerie
- IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France
| | - Pascal Morel
- Etablissement Français du Sang, La Plaine-St Denis, France.,UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France
| | - Pierre Gallian
- Etablissement Français du Sang, La Plaine-St Denis, France.,IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France
| | - Karine Lacombe
- Sorbonne Université Inserm IPLESP Hôpital St Antoine AP-HP, Paris, France
| | | |
Collapse
|
23
|
Lanteri MC, Santa-Maria F, Laughhunn A, Girard YA, Picard-Maureau M, Payrat JM, Irsch J, Stassinopoulos A, Bringmann P. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light. Transfusion 2020; 60:1319-1331. [PMID: 32333396 PMCID: PMC7317863 DOI: 10.1111/trf.15807] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 03/12/2020] [Accepted: 03/13/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND The INTERCEPT Blood System pathogen reduction technology (PRT), which uses amotosalen and ultraviolet A light treatment (amotosalen/UV-PRT), inactivates pathogens in plasma and platelet components (PCs). This review summarizes data describing the inactivation efficacy of amotosalen/UVA-PRT for a broad spectrum of viruses and parasites. METHODS Twenty-five enveloped viruses, six nonenveloped viruses (NEVs), and four parasites species were evaluated for sensitivity to amotosalen/UVA-PRT. Pathogens were spiked into plasma and PC at high titers. Samples were collected before and after PRT and assessed for infectivity with cell cultures or animal models. Log reduction factors (LRFs) were defined as the difference in infectious titers before and after amotosalen/UV-PRT. RESULTS LRFs of ≥4.0 log were reported for 19 pathogens in plasma (range, ≥4.0 to ≥7.6), 28 pathogens in PC in platelet additive solution (PC-PAS; ≥4.1-≥7.8), and 14 pathogens in PC in 100% plasma (PC-100%; (≥4.3->8.4). Twenty-five enveloped viruses and two NEVs were sensitive to amotosalen/UV-PRT; LRF ranged from >2.9 to ≥7.6 in plasma, 2.4 or greater to greater than 6.9 in PC-PAS and >3.5 to >6.5 in PC-100%. Infectious titers for four parasites were reduced by >4.0 log in all PC and plasma (≥4.9 to >8.4). CONCLUSION Amotosalen/UVA-PRT demonstrated effective infectious titer reduction for a broad spectrum of viruses and parasites. This confirms the capacity of this system to reduce the risk of viral and parasitic transfusion-transmitted infections by plasma and PCs in various geographies.
Collapse
Affiliation(s)
- Marion C Lanteri
- Department of Scientific Affairs, Cerus Corporation, Concord, California, USA
| | | | - Andrew Laughhunn
- Department of Microbiology, Cerus Corporation, Concord, California, USA
| | - Yvette A Girard
- Department of Microbiology, Cerus Corporation, Concord, California, USA
| | | | - Jean-Marc Payrat
- Department of Scientific Affairs, Cerus Europe BV, Amersfoort, The Netherlands
| | - Johannes Irsch
- Department of Scientific Affairs, Cerus Europe BV, Amersfoort, The Netherlands
| | | | - Peter Bringmann
- Department of Microbiology, Cerus Corporation, Concord, California, USA
| |
Collapse
|
24
|
Fekrazad R. Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management. PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY 2020; 38:255-257. [PMID: 32326830 DOI: 10.1089/photob.2020.4868] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Reza Fekrazad
- Radiation Sciences Research Center, Laser Research Center in Medical Sciences, AJA University of Medical Sciences, Tehran, Iran.,International Network for Photo Medicine and Photo Dynamic Therapy (INPMPDT), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| |
Collapse
|
25
|
Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev 2020; 34:75-80. [PMID: 32107119 PMCID: PMC7135848 DOI: 10.1016/j.tmrv.2020.02.003] [Citation(s) in RCA: 381] [Impact Index Per Article: 95.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 02/18/2020] [Accepted: 02/18/2020] [Indexed: 12/11/2022]
Abstract
With the outbreak of unknown pneumonia in Wuhan, China, in December 2019, a new coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), aroused the attention of the entire world. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19). The World Health Organization declared COVID-19 in China as a Public Health Emergency of International Concern. Two other coronavirus infections-SARS in 2002-2003 and Middle East Respiratory Syndrome (MERS) in 2012-both caused severe respiratory syndrome in humans. All 3 of these emerging infectious diseases leading to a global spread are caused by β-coronaviruses. Although coronaviruses usually infect the upper or lower respiratory tract, viral shedding in plasma or serum is common. Therefore, there is still a theoretical risk of transmission of coronaviruses through the transfusion of labile blood products. Because more and more asymptomatic infections are being found among COVID-19 cases, considerations of blood safety and coronaviruses have arisen especially in endemic areas. In this review, we detail current evidence and understanding of the transmission of SARS-CoV, MERS-CoV, and SARS-CoV-2 through blood products as of February 10, 2020, and also discuss pathogen inactivation methods on coronaviruses.
Collapse
Affiliation(s)
- Le Chang
- National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China; Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, PR China
| | - Ying Yan
- National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China; Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, PR China
| | - Lunan Wang
- National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China; Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, PR China; Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China.
| |
Collapse
|